Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 9Pancreatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Head and Neck Neoplasms 7Colorectal Neoplasms 7Ovarian Neoplasms 6Neoplasm Metastasis 6Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Biliary Tract Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Lymphoma, Follicular 3Kidney Neoplasms 3Cholangiocarcinoma 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Carcinoma 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Recurrence 2Oropharyngeal Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Lymphoma, T-Cell, Cutaneous 2

Interventions

Gemcitabine 4Oxaliplatin 3pembrolizumab 2tivozanib 1peposertib 1fludarabine 1durvalumab 1devimistat 1avelumab 1atezolizumab 1aldesleukin 1Temozolomide 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Pemetrexed 1Leucovorin 1Irinotecan 1Interleukin-2 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Capecitabine 1Cannabidiol 1Bortezomib 1Biopsy 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gallbladder Neoplasms × durvalumab × Clear all
NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Yonsei University

Phase 1/2 Not yet recruiting
160 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡